HUTCHMED (LON:HCM) Share Price Passes Below 200-Day Moving Average of $222.08

Shares of HUTCHMED (China) Limited (LON:HCMGet Rating) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 222.08 ($2.68) and traded as low as GBX 162.40 ($1.96). HUTCHMED shares last traded at GBX 162.40 ($1.96), with a volume of 54,536 shares changing hands.

Analyst Ratings Changes

A number of research analysts recently weighed in on HCM shares. Barclays reissued an “equal weight” rating and issued a GBX 100 ($1.21) target price on shares of HUTCHMED in a report on Tuesday, July 19th. Citigroup reissued a “buy” rating and issued a GBX 220 ($2.66) target price on shares of HUTCHMED in a report on Thursday, June 23rd.

HUTCHMED Stock Performance

The stock has a market capitalization of £1.40 billion and a PE ratio of -8.08. The business’s fifty day moving average is GBX 214.17 and its two-hundred day moving average is GBX 222.08. The company has a quick ratio of 2.97, a current ratio of 3.18 and a debt-to-equity ratio of 0.05.


(Get Rating)

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.

Recommended Stories

Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with's FREE daily email newsletter.